Evaluation of Sildenafil in Treatment of Pediatrics Pulmonary Hypertension

Evaluation of Sildenafil Pharmacokinetic Properties in Long-term Treatment of Pediatrics Pulmonary Hypertension

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138805222342N1

Enrollment

Registered

2009-10-09

Start date

2009-09-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric pulmonary hypertension. Primary pulmonary hypertension

Interventions

only intervention group, it bigins 0.5 mg/kg q12 hr and can increase up to 1 mg/kg q6hr weekly..

Treatment - Drugs

only intervention group, it bigins 0.5 mg/kg q12 hr and can increase up to 1 mg/kg q6hr weekly.

Eligibility

Sex/Gender

All

Age

1 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) patients aged 1 month to 12 year 2) mean pulmonary artery pressure of = 25 mm Hg and a normal pulmonary capillary wedge pressure (PCWP). Exclusion criteria: 1) using other vasodilators such as epoprostanol, bosentan 2) patients with systemic blood pressure <50% for the same age

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduction of pulmonary hypertension. Timepoint: 1 month. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Adverse drug reactions. Timepoint: 1 month. Method of measurement: Question and exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Badiee

Mazandaran University of Medical Sciences

amir11aina@yahoo.com+98 15 1223 3014

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026